[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Acesion Pharma\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":45},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,1,0,[8],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":28,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100613542","phase-2-clinical-phase-2-trial-of-ap31969-versus-placebo-for-rhythm-control-of-atrial-fibrillation-100613542",false,"NCT07267949","Clinical Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation","Clinical Randomised Phase 2 Trial of AP31969 Versus Placebo for Rhythm Control of Atrial Fibrillation","END-AF-1","Inclusion Criteria:\n\n* Willing and able to provide written informed consent.\n* Age 18 or older.\n* ECG documented diagnosis of paroxysmal or persistent AF.\n* AF history at screening indicating an expected AF burden of 1-90%, i.e., at least 1 self-terminating AF episode within 4 months prior to the screening visit.\n* AF burden of ≥ 1% and ≤ 90% assessed with an ECG patch device during the screening period prior to the randomisation visit.\n* Investigator and participant agreement to avoid non-trial related rhythm control intervention for the duration of the trial, including:\n\n  * Antiarrhythmic drug class I and\u002For III (including amiodarone)\n  * Electrical or pharmacological cardioversion\n  * AF ablation procedure\n* Willing to have a loop recorder implanted.\n\nExclusion Criteria:\n\n* Prior AF ablation procedure other than pulmonary vein isolation (PVI) only.\n* Any of the following events within 4 weeks prior to the screening visit: Myocardial infarction, Unstable angina pectoris, Stroke or transient, ischaemic attack, Percutaneous coronary intervention (PCI), Coronary artery bypass graft (CABG), Peripheral revascularisation procedure.\n* Cardiac pacing device e.g. pacemaker and cardiac resynchronization therapy device with atrial or ventricular pacing for \\> 5% of the time or existing implantable loop recorder.\n* Heart failure, New York Heart Association class III (3) or IV (4).\n* Left ventricular ejection fraction \\\u003C 40% based on imaging (e.g. echocardiography) performed within 6 months prior to or during the screening visit.\n* Clinically significant valvular heart disease, including severe aortic stenosis, severe mitral regurgitation and\u002For severe mitral stenosis, in the opinion of the investigator.\n* QTc (Fridericia, QTcF) interval \\> 450 ms for males and \\> 470 ms for females at screening.\n* eGFR \\\u003C60 mL\u002Fmin \u002F1.73 m² based on creatine and CKD-EPI formula\n* Use of antiarrhythmic drug class I and\u002For III within 7 days or, for amiodarone, within 3 months prior to the screening visit.","ALL","18 Years",{"count":20,"type":21},200,"ESTIMATED","INTERVENTIONAL",[24],"PHASE2","A clinical Randomized Phase 2 Trial of AP31969 versus Placebo for Rhythm Control of Atrial Fibrillation.",[27],"Atrial Fibrillation (AF)",[29,30,31],"Atrial Fibrillation","AP31969","SK channel inhibitor","RECRUITING","2026-06-10",{"date":35,"type":36},"2026-06-12","ACTUAL",{"date":38,"type":36},"2025-10-22",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"Acesion Pharma","INDUSTRY",44,""]